• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Sunshine Biopharma Inc.

    10/23/25 4:56:54 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SBFM alert in real time by email
    DEFA14A 1 sunshine_defa14a.htm FORM DEFA 14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

     

    SCHEDULE 14A

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a)

    of the Securities Exchange Act of 1934

    (Amendment No.1)

     

    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material under Rule 14a-12

     

    Sunshine Biopharma Inc.

    (Name of Registrant as Specified in its Charter)

     

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

     

    No fee required.
    ☐ Fee paid previously with preliminary materials

      

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

       

     

     

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V80829 - P39827 SUNSHINE BIOPHARMA INC. 333 LAS OLAS WAY, CU4 SUITE 433 FORT LAUDERDALE, FL 33301 SUNSHINE BIOPHARMA INC. 2025 Annual Meeting Vote by December 10, 2025 11:59 PM ET You invested in SUNSHINE BIOPHARMA INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on December 11, 2025. Get informed before you vote View the Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to November 27, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually at the Meeting* December 11, 2025 10:00 a.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/SBFM2025

       

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. For 1. To elect five (5) persons to our Board of Directors, until the 2026 Annual Meeting of Shareholders and until their successors are duly elected and qualified; 1) Dr. Steve N. Slilaty 2) Mr. Camille Sebaaly 3) Dr. Rabi Kiderchah 4) Mr. David Natan 5) Dr. Andrew Keller For 2. To ratify the appointment of M&K CPAS, PLLC as the Company’s independent registered public accountant to audit the Company’s financial books and records for its fiscal year ending December 31, 2025. For 3. To approve an amendment to the Company’s 2023 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder to 683,000. Voting Items Board Recommends V80830 - P39827

       

    Get the next $SBFM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SBFM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SBFM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Slilaty Steve N. bought $10,000 worth of Series B Preferred Stock (100,000 units at $0.10), increasing direct ownership by 333% to 130,000 units (SEC Form 4)

    4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

    3/5/24 4:05:35 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Slilaty Steve N. bought $2,000 worth of Series B Preferred Stock (20,000 units at $0.10), increasing direct ownership by 200% to 30,000 units (SEC Form 4)

    4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

    2/12/24 4:05:15 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SBFM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

    FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs.The newly launched drugs are Olanzapine and Olanzapine ODT. Olanzapine is a generic version of Zyprexa®. Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders. Olanzapine is also indicated for the acute treatment of manic or mixed episodes of bipolar I disorder.

    1/21/25 8:00:00 AM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

    FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pleased to announce the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives.In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutic

    1/15/25 8:00:00 AM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

    FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has developed an orally active protease inhibitor with dose-dependent antiviral activity in mice infected with SARS Coronavirus (SARS-CoV-2).There are still unmet medical needs for agents to combat SARS-CoV-2 infections. SARS-CoV-2 is the etiologic agent of COVID-19 and one of three types of Coronavirus that cause Severe Acute Respiratory Syndrome (SARS). SARS-CoV-2 undergoes mutation at a rapid rate, which leads to the con

    12/9/24 7:30:00 AM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SBFM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Roy Michel claimed ownership of 1 shares (SEC Form 3)

    3 - Sunshine Biopharma Inc. (0001402328) (Issuer)

    1/21/25 8:20:21 AM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Slilaty Steve N. bought $10,000 worth of Series B Preferred Stock (100,000 units at $0.10), increasing direct ownership by 333% to 130,000 units (SEC Form 4)

    4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

    3/5/24 4:05:35 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Slilaty Steve N. bought $2,000 worth of Series B Preferred Stock (20,000 units at $0.10), increasing direct ownership by 200% to 30,000 units (SEC Form 4)

    4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

    2/12/24 4:05:15 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SBFM
    SEC Filings

    View All

    Sunshine Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Sunshine Biopharma Inc. (0001402328) (Filer)

    12/12/25 4:05:29 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Sunshine Biopharma Inc.

    10-Q - Sunshine Biopharma Inc. (0001402328) (Filer)

    11/13/25 4:07:16 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Sunshine Biopharma Inc.

    DEFA14A - Sunshine Biopharma Inc. (0001402328) (Filer)

    10/23/25 4:56:54 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SBFM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sunshine Biopharma Inc.

    SC 13G/A - Sunshine Biopharma Inc. (0001402328) (Subject)

    11/14/24 4:28:14 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sunshine Biopharma Inc.

    SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)

    2/23/24 4:03:01 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sunshine Biopharma Inc.

    SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)

    2/21/24 4:28:39 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SBFM
    Leadership Updates

    Live Leadership Updates

    View All

    Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

    FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pleased to announce the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives.In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutic

    1/15/25 8:00:00 AM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SBFM
    Financials

    Live finance-specific insights

    View All

    Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

    MONTREAL, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. As such, Nora Pharma Inc. is now a wholly owned subsidiary of Sunshine Biopharma Inc. Nora Pharma is one of North America's fastest growing generic pharmaceuticals companies. The addition of Nora Pharma allows Sunshine Biopharma to expand its operations into the area of generic prescription drugs and biosimilars. The purchase price of $30,000,000 Canadian (approxi

    10/20/22 8:00:00 AM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care